Selective Intraarterial Radiotherapy (SIRT) with QuiremSpheres: Evaluation of renal and intestinal radioactivity excretion after the Holmium Scout Dose for therapy planning and after SIRT procedures – Aspects of radiation protection and safety

• Conditions: C22.0; Liver cell carcinoma; C78.7; Secondary malignant neoplasm of liver and intrahepatic bile duct

• Registration Number: DRKS00021427
• Lead Sponsor: niversitätsklinikum Jena

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-04-17
• Study Completion: 2021-11-14
• Results First Posted: 2022-12-22
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

Patients with primary (HCC, CCC) and secondary (metastases) malignant liver tumors may undergo SIRT, depending on previous treatments, other clinical, laboratory and imaging data.

Exclusion Criteria

Patients with SIRT contraindications (e.g. high tumor load, impaired liver function)

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To measure the renal and intestinal excretion of Holmium-166 during the first 48h after application of the Scout Dose and after application of the treatment dose.

Secondary Outcome Measures

Name	Time	Method
To gain experience using the Holmium Scout Dose, to evaluate the side effect profile of this and of the SIRT with QuiremSpheres. A potential sub-project would be to measure to radiation exposure to the nuclear medicine physician and the radiologist during the procedures.